Evercore ISI cuts Foghorn Therapeutics stock rating on trial failure
Covered in this story
What has happened since
- Evercore is down 3.2% since this was published, 9 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Foghorn Therapeutics Inc
- H.C. Wainwright: $2.02 → $5 by Oct 2027 · Buy via Investing.com
- Stifel: $2.92 → $5 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $FHTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Foghorn Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.